Ads
related to: current research on hemophilia- FAQs
Get Answers To Frequently Asked
Questions About Hemophilia A
- Financial Assistance
Learn More About The Financial
Resources Available To You
- Get One-On-One Support
Connect With An Account & Community
Manager For Hemophilia Support
- Patient Stories
Hear Unique Stories and Experiences
From Real Hemophilia A Patients
- Questions For Your Doctor
Learn The Right Questions To Ask
Your Doctor About Hemophilia A
- Clinical Trial Results
View Information And Results
From Hemophilia Clinical Trials
- FAQs
Search results
Results From The WOW.Com Content Network
The National Bleeding Disorders Foundation was founded in 1948, as the first national hemophilia advocacy organization in the United States. [2] One of its early initiatives was to secure funding for Comprehensive Hemophilia Diagnostic and Treatment Centers (HTC).
Hemophilia can be treated with gene therapy, which is an area of ongoing research. Hemophilia A and hemophilia B gene therapy treatments have been approved by the FDA in recent years. Hemophilia individuals may be able to benefit from genetic treatments that can provide the missing clotting factors for a long time to come
Haemophilia (British English), or hemophilia (American English) [6] (from Ancient Greek αἷμα (haîma) 'blood' and φιλία (philía) 'love of'), [7] is a mostly inherited genetic disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding.
World Hemophilia Day is held annually on April 17 by the WFH. [11] It is an awareness day for hemophilia and other bleeding disorders, [12] which also serves to raise funds and attract volunteers for the WFH. [13] It was started in 1989; April 17 was chosen in honor of Frank Schnabel's birthday. [14] [15]
In the US, fidanacogene elaparvovec is indicated for the treatment of adults with moderate to severe hemophilia B (congenital factor IX deficiency) who currently use factor IX prophylaxis therapy; or have current or historical life-threatening hemorrhage; or have repeated, serious spontaneous bleeding episodes; and do not have neutralizing antibodies to adeno-associated virus serotype Rh74var ...
Acquired haemophilia A (AHA) is a rare but potentially life-threatening bleeding disorder characterized by autoantibodies directed against coagulation factor VIII.These autoantibodies constitute the most common spontaneous inhibitor to any coagulation factor and may induce spontaneous bleeding in patients with no previous history of a bleeding disorder.
Ads
related to: current research on hemophilia